IL281188A - Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides - Google Patents
Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptidesInfo
- Publication number
- IL281188A IL281188A IL281188A IL28118821A IL281188A IL 281188 A IL281188 A IL 281188A IL 281188 A IL281188 A IL 281188A IL 28118821 A IL28118821 A IL 28118821A IL 281188 A IL281188 A IL 281188A
- Authority
- IL
- Israel
- Prior art keywords
- polypeptides
- methods
- polycyclic compounds
- rapidly accelerated
- targeted degradation
- Prior art date
Links
- 201000008808 Fibrosarcoma Diseases 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728581P | 2018-09-07 | 2018-09-07 | |
| PCT/US2019/050114 WO2020051564A1 (en) | 2018-09-07 | 2019-09-07 | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL281188A true IL281188A (en) | 2021-04-29 |
Family
ID=68051923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL281188A IL281188A (en) | 2018-09-07 | 2021-03-02 | Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3846907A1 (ko) |
| JP (2) | JP2022500368A (ko) |
| KR (2) | KR20240028539A (ko) |
| CN (1) | CN113164775A (ko) |
| AU (2) | AU2019335516B2 (ko) |
| CA (1) | CA3109981A1 (ko) |
| IL (1) | IL281188A (ko) |
| MX (1) | MX2021002559A (ko) |
| WO (1) | WO2020051564A1 (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CA3162266A1 (en) * | 2019-12-17 | 2021-06-24 | Nikolai Kley | Bifunctional agents for protein recruitment and/or degradation |
| EP4129402A1 (en) * | 2020-03-31 | 2023-02-08 | Mitsubishi Tanabe Pharma Corporation | Hydroxypyrrolidine derivative and medicinal application thereof |
| WO2021255213A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
| TW202214627A (zh) | 2020-06-19 | 2022-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｂｒａｆ降解劑 |
| JP2023539663A (ja) * | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022266206A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| BR112023025403A2 (pt) | 2021-06-25 | 2024-02-20 | Korea Res Inst Chemical Tech | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
| WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| WO2023098656A1 (en) * | 2021-11-30 | 2023-06-08 | Beigene, Ltd. | Compounds for the degradation of egfr kinase |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| WO2024089272A1 (en) * | 2022-10-28 | 2024-05-02 | Institut National De La Sante Et De La Recherche Medicale | New inhibitors of phosphatidylinositol 3-kinase |
| CN115806503A (zh) * | 2022-12-02 | 2023-03-17 | 中国海洋大学 | 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007522116A (ja) | 2004-01-16 | 2007-08-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | コンホメーションが制約されたＳｍａｃ模倣物およびその使用 |
| EP1740173A4 (en) | 2004-03-23 | 2009-05-27 | Genentech Inc | AZABICYCLOOCTAN IAP INHIBITORS |
| JP4691549B2 (ja) | 2004-04-07 | 2011-06-01 | ノバルティス アーゲー | Ｉａｐの阻害剤 |
| KR100984459B1 (ko) | 2004-07-02 | 2010-09-29 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| WO2008014236A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| EP2139490B1 (en) | 2007-04-13 | 2014-07-02 | The Regents of the University of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| KR102204989B1 (ko) | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| US9637518B2 (en) | 2013-07-12 | 2017-05-02 | Bristol-Myers Squibb Company | IAP antagonists |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX2016013563A (es) * | 2014-04-14 | 2017-05-09 | Arvinas Inc | Moduladores de la proteolisis basados en imida y metodos de uso asociados. |
| GB201504314D0 (en) * | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| EP3544957A4 (en) * | 2016-11-22 | 2020-09-02 | Dana-Farber Cancer Institute, Inc. | KINASE PROTEIN DEGRADATION BY CONJUGATION OF KINASE PROTEIN INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE |
| KR102564201B1 (ko) * | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
-
2019
- 2019-09-07 JP JP2021512854A patent/JP2022500368A/ja active Pending
- 2019-09-07 CA CA3109981A patent/CA3109981A1/en active Pending
- 2019-09-07 KR KR1020247005115A patent/KR20240028539A/ko active Application Filing
- 2019-09-07 CN CN201980073600.1A patent/CN113164775A/zh active Pending
- 2019-09-07 WO PCT/US2019/050114 patent/WO2020051564A1/en unknown
- 2019-09-07 AU AU2019335516A patent/AU2019335516B2/en active Active
- 2019-09-07 EP EP19773614.3A patent/EP3846907A1/en active Pending
- 2019-09-07 KR KR1020217009937A patent/KR102642203B1/ko active IP Right Grant
- 2019-09-07 MX MX2021002559A patent/MX2021002559A/es unknown
-
2021
- 2021-03-02 IL IL281188A patent/IL281188A/en unknown
-
2022
- 2022-09-08 AU AU2022228150A patent/AU2022228150A1/en active Pending
-
2023
- 2023-08-03 JP JP2023127233A patent/JP2023159166A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019335516A1 (en) | 2021-03-11 |
| KR20240028539A (ko) | 2024-03-05 |
| MX2021002559A (es) | 2021-07-21 |
| CN113164775A (zh) | 2021-07-23 |
| CA3109981A1 (en) | 2020-03-12 |
| JP2022500368A (ja) | 2022-01-04 |
| KR102642203B1 (ko) | 2024-03-04 |
| WO2020051564A1 (en) | 2020-03-12 |
| EP3846907A1 (en) | 2021-07-14 |
| JP2023159166A (ja) | 2023-10-31 |
| AU2019335516B2 (en) | 2022-06-16 |
| KR20210073519A (ko) | 2021-06-18 |
| AU2022228150A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281188A (en) | Polycyclic compounds and methods for targeted reduction of rapidly accelerating fibrosarcoma polypeptides | |
| IL304704A (en) | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma | |
| KR102094830B9 (ko) | 다환 방향족 유도체 화합물 및 이를 이용한 유기발광소자 | |
| EP3559006A4 (en) | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | |
| HK1249058A1 (zh) | 用於增强靶向蛋白質降解的化合物和方法 | |
| EP3526202A4 (en) | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | |
| IL271025A (en) | Multibiotic substances and methods of using them | |
| EP3337476A4 (en) | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN | |
| IL273664A (en) | Fill-finish assemblies and related methods | |
| IL274534A (en) | Processes for the separation of benzodiazepine-2-ones and benzodiazepine-2-one derivatives | |
| AU2018297285A1 (en) | Compositions and methods for treating or preventing endocrine FGF-linked diseases | |
| EP3328898B8 (en) | Trkb or trkc agonist compositions and methods for the treatment of otic conditions | |
| EP3645739A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA | |
| EP3612215A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia | |
| EP3423100A4 (en) | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF | |
| EP3595596A4 (en) | TRANSLUMINAL RELEASE DEVICES AND ASSOCIATED KITS AND PROCEDURES | |
| IL288370A (en) | Methods and devices for patient-derived microorganospheres | |
| EP3654956A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH AN IMPRINTING DEFECTIVE | |
| IL280218A (en) | Methods for the treatment of HFPEF using dapagliflozin and compounds containing it | |
| EP3490584A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MELANOMA | |
| EP3836941A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUCOSITIS | |
| EP3762363A4 (en) | POLYCYCLIC AROMATIC COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF | |
| EP3781945A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS | |
| EP3659125C0 (en) | LOCK AND DEVICE PROVIDED THEREOF | |
| AU2018301500A1 (en) | Methods and compositions for treating inflammation |